Michael R. Hayden - May 18, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Cassandra Robinson, Attorney-in-fact
Stock symbol: XENE
Transactions as of: May 18, 2021
Transactions value $: $13,475
Form type: 4
Date filed: 5/20/2021, 04:13 PM
Next filing: Jun 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Options Exercise	$13.5K	+3.5K	+3.11%	$3.85	116K	May 18, 2021	Direct	F1
holding	XENE	Common Shares						92.1K	May 18, 2021	By Genworks Inc.	F2
holding	XENE	Common Shares						114K	May 18, 2021	By wife

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-3.5K	-100%	$0.00^*	0	May 18, 2021	Common Shares	3.5K	$3.85	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021.
F2	Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.
F3	One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. The original grant date of the option is June 1, 2017.